ACTRN12621000323820招募中1 期
Phase I open-label clinical trial of allogeneic multi-virus-specific T cells for the treatment of viral complications in transplant recipients
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1. Aged 18 years or above
- •2. Previously received a solid organ transplant (kidney, lung, heart, liver, or a combination of these)
- •3. Viral infection or virus-induced neoplasia due to CMV, EBV, BKV or AdV, which is proven or suspected to be refractory to standard of care, or where standard of care is relatively or absolutely contraindicated.
- •4. Availability of a suitable batch of IP
排除标准
- •1. Significant non-malignant disease, e.g. severe cardiac or respiratory dysfunction
- •2. Uncontrolled psychosis, substance dependence, or any other psychiatric condition that may compromise the ability to participate in this trial
- •3. Prior cancers except: cancers with no evidence of disease recurrence and clinical expectation of recurrence of <5%; successfully treated non-melanoma skin cancer; localised prostate cancer; or carcinoma in situ of the cervix; or virus-induced neoplasia as specified in inclusion criterion 3.
- •4. Women who are pregnant, lactating or unwilling to use adequate contraception
- •5. Any other medical condition that, in the view of the Clinical Investigator, would prohibit participation
研究者
相似试验
招募中
1 期
SARS-CoV-2-specific T cell therapy for COVID-19SARS-CoV-2Infection - Other infectious diseasesRespiratory - Other respiratory disorders / diseasesACTRN12622000377730QIMR Berghofer Medical Research Institute20
终止
1 期
A clinical trial of adoptive T-cell immunotherapy for patients with Epstein-Barr virus-associated nasopharyngeal carcinoma.Metastatic nasopharyngeal carcinomaCancer - Head and neckACTRN12613000866707QIMR Berghofer Medical Research Institute18
已完成
不适用
Phase I clinical trial of newly developed antigen peptide vaccine for advanced esophageal cancerAdvanced esophageal squamous cell carcinoma patietns treated with standart therapy includingn surgery, chemotherapy and radiotherapy, and all these treatments were failed.JPRN-UMIN000004662Chiba University5
进行中（未招募）
1 期
Phase I clinical trial on the use of fresh, allogeneic, second-generation CD19-CAR T cells for treatment of children and young adult with relapsed/refractory B-cell Acute Lymphoblastic LeukemiaRelapsed/refractory B-cell Acute Lymphoblastic LeukemiaCTIS2023-508420-36-00Ospedale Pediatrico Bambino Gesu'24
进行中（未招募）
1 期
A study to find and investigate a safe dose of BI 836858 in combination with decitabine for patients with acute myeloid leukemia (AML)patients with acute myeloid leukemiaMedDRA version: 19.1Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864EUCTR2015-002892-30-ESBoehringer Ingelheim España, S.A.200